ASX Filings
Read about Tryptamine Therapeutics Limited on the ASX
Previous Press Releases of Tryp
on the Canadian securities exchange
Read about Tryp Therapeutics on Sedar
All News
See below for a comprehensive list of news items published by Tryp Therapeutics.
Tryp Therapeutics Inc. Announces Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3.0 Million
November 2, 2023 Kelowna, Canada – November 2, 2023 – Tryp Therapeucs, Inc. (“Tryp” or the “Company”) (CSE: TRYP), a…
Tryp Therapeutics Announces Appointment of CEO and Private Placement of Unsecured Convertible Debentures for Gross Proceeds of up to AUD$175,000
October 4 2023 Kelowna, Canada – October 4 2023 – Tryp Therapeutics Inc. (“Tryp” or the “Company”) (CSE: TRYP)announces that,…
Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer
AUGUST 04, 2023 Kelowna, Canada, August 3, 2023 – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”),…
Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Clinical Trial in Patients with IBS at Massachusetts General Hospital
Kelowna Canada, (July 13 2023) — Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company…
Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients with IBS at Massachusetts General Hospital
Kelowna Canada, (May, 24 2023) — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology…
Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of SecuredConvertible Debentures for Gross Proceeds of AUD$2,400,000
April 27 2023 Kelowna, Canada – April 27 2023 – Tryp Therapeutics Inc. (“Tryp” or the “Company”) (CSE: TRYP), a…